ClinicalTrials.gg
Active, not recruitingNCT04274426MIROVAUpdated May 13, 2026

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

A Phase 2 interventional study of Carboplatin and Pegylated liposomal doxorubicin (PLD) in Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma, sponsored by AGO Research GmbH. Active, not recruiting at 19 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by AGO Research GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a multi-center, randomized, two-arm, open-label, comparative phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy.

Read the detailed description

136 patients will be randomized into the follow-ing two treatment arms as specified below:

Arm A: Control arm Platinum-based chemotherapy Arm B: Carboplatin + Mirvetuximab soravtansine (IMGN853)

02

Conditions studied

  • Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
03

In context

Lead sponsor

AGO Research GmbH is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients must have a documented, definite diagnosis of epithelial cancer of the ovary, the fallopian tube or the peritoneum
  2. disease with a platinum-free interval >3 months
  3. All histologic subtypes of ovarian carcinoma including carcinosarcoma (malignant mixed Mullerian tumors, MMMT)
  4. Patients with wildtype BRCA1/2 mutation status or with a deleterious BRCA1/2 mutation in germline or somatic testing if they underwent PARP inhibitor therapy in previous treatment line.
  5. Patients must be willing to provide from current relapse or previous surgeries/biopsies for central confirmation of FRα high status by PS2+ scoring:

    all tumors must exhibit ≥75% of tumor cells with FRα membrane staining and ≥ 2+ intensity by immunohistochemistry (IHC) using the Ventana FOLR1 (FOLR1 2.1) CDx assay.

  6. Patients must have or evaluable disease in combination with GCIG CA-125 criteria.
  7. Patients had one or more . The last line of chemotherapy must have included platinum (min. 4 cycles) and has resulted in a partial or complete response.
  8. Major surgery (not including placement of vascular access device, tumor punch/scrape biopsies or secondary wound closure) must be completed four weeks prior to Day 1.
  9. Patients must have adequate hematological, liver, cardiac and kidney function:

    1. ≥ 10.0 g/dL.
    2. (ANC) ≥ 1.5 x 109/L
    3. count ≥ 100 x 109/L.
    4. Total ≤ 1.5 x institutional (ULN).
    5. /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase/Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2.5 x ULN, unless liver are present in which case they must be ≤ 5 x ULN.
    6. Serum creatinine ≤ 1.5 x institutional ULN and of at least 40 ml/minute according to Cockroft-Gault formula.
  10. Patient is female and ≥18 years of age at the time of the first screening visit.
  11. (ECOG) performance status (PS) 0 or 1.
  12. Patients must be willing and able to sign the form, and to adhere to the study visit schedule and other protocol requirements.
  13. Women of (a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming unless permanently ster-ile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must have a negative serum pregnancy test within 3 days from day 1 of cycle 1 and agree to use a highly effective method of while on study treatment and for at least 8 months after end of treatment. Such methods include:

    1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

      • oral
      • intravaginal
      • transdermal
    2. Progestogen-only hormonal contraception associated with inhibition of ovulation:

      • oral
      • injectable
      • implantable
    3. Intrauterine device (IUD)
    4. Intrauterine hormone-releasing system (IUS)
    5. Bilateral tubal occlusion
    6. Vasectomized partner
    7. Sexual abstinence

Exclusion criteria

Exclusion Criteria:

  1. Non-epithelial tumor origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors)
  2. Ovarian tumors of low malignant potential (e.g. borderline tumors).
  3. Unknown BRCA status.
  4. Patients who are planned to receive bevacizumab for the current relapse.
  5. Other within the last 3 years (except cervix or breast in situ carcinoma, type I stage I endometrial cancer)
  6. Patients who underwent surgery for the current relapse with macroscopic complete resection
  7. Prior systemic anticancer therapy within 28 days before randomization
  8. Prior treatment with folate receptor-targeting agents is not allowed.
  9. Patients with > Grade 1 peripheral neuropathy.
  10. Serious concurrent illness or clinically-relevant active infection
  11. Previous clinical diagnosis of non-infectious interstitial lung disease, including non-infectious pneumonitis.
  12. Active or chronic corneal disorders such as Sjogren's syndrome, Fuchs corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, active ocular conditions requiring ongoing treatment/monitoring such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision. Active or chronic corneal disorder
  13. Required use of folate-containing supplements (e.g. folate deficiency)
  14. Women of (WOCBP) not protected by highly effective methods.
  15. Pregnant and/or breast-feeding women.
  16. Known to one of the chemotherapy re-gimes and/or PARP inhibitors and/or any of their .
  17. Patients with prior hypersensitivity to monoclonal antibodies.
  18. Patients with potential risks according to , warnings or interactions of the used chemotherapeutic agents as stated in the SmPCs are not eligible for participation in this trial.
  19. Patients with untreated or symptomatic central nervous system (CNS)
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Active comparator
    Control arm with Platinum-based chemotherapy

    1. Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d 2. Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 \& d8) q21d 3. Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d

    Drug: Carboplatin · Drug: Pegylated liposomal doxorubicin (PLD) · Drug: Gemcitabine · Drug: Paclitaxel

  • Experimental
    Carboplatin + Mirvetuximab soravtansine (IMGN853)

    Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.

    Drug: Carboplatin · Drug: Mirvetuximab Soravtansine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) defined as the time from randomization to progressive disease (PD) or death, whichever occurs earlier. PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

    PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

    Time frame: Up to 2.5 years. From date of randomization until date of progressive disease (PD) or death, whichever occurs earlier.

Secondary outcomes

  1. OS

    Overall survival

    Time frame: Up to 2.5 years. From date of randomization until date of death from any cause.

  2. ORR

    Objective response rate

    Time frame: Up to 2.5 years. From date of randomization to date of death death from any cause.

  3. Efficacy regarding PFS

    Efficacy regarding Progression Free Survival depending on histologic subtype

    Time frame: Up to 2.5 years. From date of randomization to date of death from any cause.

  4. Efficacy regarding OS

    Efficacy regarding Overall Survival depending on histologic subtype

    Time frame: Up to 2.5 years. From date of randomization to date of death from any cause.

  5. Efficacy regarding ORR

    Efficacy regarding Objective Response Rate depending on histologic subtype

    Time frame: Up to 2.5 years. From date of randomization to date of death from any cause.

  6. Serological progressive disease

    Time to serological progressive disease according to GCIG criteria

    Time frame: Up to 2.5 years. From date of randomization to date of death death from any cause.

  7. Time to first subsequent treatment (TFST)

    Time to first subsequent treatment (TFST)

    Time frame: Up to 2.5 years. From date of randomization to date of death from any cause.

  8. Time to second subsequent treatment (TSST)

    Time to second subsequent treatment (TSST)

    Time frame: Up to 2.5 years. From date of randomization until date of death from any cause.

  9. Patient-reported outcomes

    Quality of Life (EORTC C-30)

    Time frame: Up to 2.5 years. From date of randomization until date of death from any cause.

  10. Patient-reported outcomes

    Quality of Life (EORTC OV28)

    Time frame: Up to 2.5 years. From date of randomization until date of death from any cause.

  11. Safety and tolerability

    Safety and tolerability of the used drugs evaluated by NCI CTCAE v5.0

    Time frame: Up to 2.5 years. From date of randomization until date of death from any cause through study completion.

07

Study locations

19 sites
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2025, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2020
First posted
Feb 18, 2020
StartActual
Oct 13, 2021
Primary completionActual
Dec 3, 2025
CompletionEst.
Dec 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04274426
Lead sponsor
AGO Research GmbH
Responsible party
Sponsor
First posted
Feb 18, 2020
Start date
Oct 13, 2021
Primary completion
Dec 3, 2025
Completion
Dec 2026 (estimated)
Last update
May 13, 2026

Study contacts

Philipp Harter
study chair · Evangelische Kliniken Essen-Mitte, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion